Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.

Chao-Yang MengShiyu SunYong LiangHairong XuChao ZhangMin ZhangFu-Sheng WangYang-Xin FuHua Peng

Published in: Gut (2022)

Targeting the liver with an engineered anti-PDL1-IFNα heterodimer can break HBV-induced immune tolerance to an HBsAg vaccine, offering a promising translatable therapeutic strategy for the functional cure of CHB.

Keyphrases

hepatitis b virus
dendritic cells
immune response
liver failure
high glucose
drug induced
endothelial cells